Back to results
US 2021/0260076 A1Published application
Fulvestrant formulations
AssigneeEagle Pharmaceuticals, Inc.
InventorNageswara R. Palepu
Life of this patent
Estimating the term…
Abstract
Fulvestrant formulations suitable for intramuscular injection at concentration in excess of 40 mg/ml in the absence of castor oil and castor oil derivatives are disclosed.
Claims17
A fulvestrant formulation, comprising at least 40 mg/ml fulvestrant in a pharmaceutically acceptable vehicle therefor which comprises glycofurol, said formulation being substantially free of castor oil and castor oil derivatives.
A solvent blend for fulvestrant having the ability to dissolve fulvestrant in excess of 40 mg/ml, comprising:
- (A) glycofurol alone or in conjunction with one or more members selected from the group consisting of polyethylene glycols, poloxamers, reverse poloxamers, propylene glycol, dihydrolipoic acid, and mixtures thereof;
- (B) dihydrolipoic acid alone or in conjunction with one or more members selected from the group consisting of polyethylene glycols, poloxamers, reverse poloxamers, and mixtures thereof;
- (C) polyethylene glycol in combination with at least one of a polxamer, a reverse poloxamer, or propylene glycol;
- and
- (D) optionally a compatible co-solvent compatible with fulvestrant;
- said solvent blend being substantially free of water, and substantially free of castor oil and castor oil derivatives.
3 more elements
Dependencies are inferred from the claim text.